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A B S T R A C T
Purpose: There is a strong scientiﬁc rationale to support the view that cytochrome P450 (CYP P450)
enzyme-inducing AEDs induce bone loss in patients with epilepsy. However, no study has investigated
the association between CYP 2C9 polymorphism and bone mineral density (BMD), 25-hydroxyvitamin D
or parathyroid hormone levels in patients with epilepsy. This study sought to determine the association
between BMD and CYP 2C9 polymorphism.
Methods: Ninety-three patients taking phenytoin as monotherapy were examined for CYP 2C9
polymorphism, vitamin D level and parathyroid hormone level and underwent basic chemistry testing.
The bone mineral density of the lumbar spine and left femur were measured using dual-energy X-ray
absorptiometry.
Results: The results indicated that about 18.3% of the patients with epilepsy were positive for CYP2C9*3.
Furthermore, bone mineral density was associated with CYP 2C9 polymorphism epileptic patients.
Speciﬁcally, patients with 2C9 polymorphism had higher T-scores and Z-scores of the femoral neck
(p = 0.02 and 0.04, respectively), but not of the lumbar spine (p = 0.27 and 0.06, respectively). There was
also a trend of having higher serum PTH levels and statistically signiﬁcantly lower 25-hydroxyvitamin D
levels in patients with wild type than in those compared with CYP 2C9 polymorphism (p = 0.05 and 0.03,
respectively). Additionally, the patients with CYP 2C9 polymorphism had higher plasma levels of
phenytoin, particularly when compared with those with wild type (p = 0.01). However, there was no
association between serum levels of phenytoin and low BMD at femoral neck or lumbar spine.
Conclusion: CYP 2C9 polymorphism is associated with higher BMD, independent of plasma levels of
phenytoin.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eizPrevious studies of bone health in epilepsy patients have
reported signiﬁcant variability in the prevalence of low bone
mineral density, ranging from 26% to 75% depending on ethnici-
ty.1–4 There is a strong scientiﬁc rationale to support the view that
cytochrome P450 (CYP P450) enzyme-inducing AEDs increase the
catabolism of the active forms of vitamin D to inactive metabolites.
This, in turn, should lead to an increase in parathyroid hormone
(PTH) levels, which is required for the body to convert more
vitamin D into its active forms, and this increase in PTH would then
cause an increase in bone turnover, with resultant bone loss over
time.5 Other possible mechanism in respect to the production of
osteopenia by phenytoin could be the direct effects of local factors* Corresponding author. Tel.: +66 74451452; fax: +66 74429385.
E-mail address: pkanitpo@medicine.psu.ac.th (K. Phabphal).
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http://dx.doi.org/10.1016/j.seizure.2013.06.003that regulate bone turnover.6 Previous studies have reported an
association between serum phenytoin level and BMD or the blood
bone biomarkers.7,8 Nakade et al. have reported direct evidence
that low doses of phenytoin can stimulate the proliferation,
differentiation, and maturation of osteoclasts in in vitro human
craniofacial bone cells.8 Moreover, Lau et al., who conducted a
study on phenytoin-treated patients, found that serum levels of
osteocalcin, skeletal alkaline phosphatase, and procollagen pep-
tides were signiﬁcantly elevated in phenytoin-treated patients
compared to age-matched subjects; in each case these biochemical
markers were signiﬁcantly correlated with serum phenytoin
level.7
Cytochrome P450 has been identiﬁed as a major catabolic
enzyme for phenytoin; it converts phenytoin to its hydroxylated
form in the liver. Recently, two single nucleotide polymorphisms
(SNPs) in the coding region of CYP2C9 were identiﬁed in the mostvier Ltd. All rights reserved.
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that have signiﬁcant clinical importance are CYP2C9*2 and
CYP2C9*3; CYP2C9*1 refers to the wild-type gene. The identiﬁed
mutant alleles of CYP2C9, CYP2C9*2 and CYP2C9*3 have respec-
tively a 70% and 3–5% enzymatic activity compared to the wild-
type gene.9 Additionally, these gene polymorphisms, especially
2C9*2 and 2C9*3, have been found to affect bone mineral density
(BMD).
However, the previous studies were conducted on the facial
bone8 and measured only serum markers of osteogenesis, not bone
mineral density.6,7 To our knowledge, no studies focusing on the
association between phenytoin level and bone mineral density at
other sites, speciﬁcally the lumbar spine and femoral neck, and
investigating their susceptibility to fracture, have been reported.1–
4 Furthermore, to date, no study has investigated the association
between CYP 2C9 polymorphism and BMD or 25-hydroxyvitamin
D or parathyroid hormone levels in young adults taking phenytoin.
This study was conducted to evaluate whether 2C9 polymor-
phism has any effect on phenytoin metabolism and subsequent
serum phenytoin concentration, and to examine the association
between 2C9 polymorphism and BMD.
1. Subjects and methods
1.1. Subjects
We performed a cross-sectional study and recruited young Thai
ambulatory adults with focal onset epilepsy, who had attended the
general medical or neurological clinics of Songklanagarind
Hospital between October 2010 and April 2012. Before recruit-
ment, the patients completed a questionnaire focusing on age, age
at onset of epilepsy, sex, drug use, medical history including
epilepsy characteristics, and presence of conditions known to
affect bone turnover and BMD. The information obtained from the
patients was rechecked with their medical records and, in some
cases, by contacting their physicians.
The inclusion criteria were: a Thai national with focal onset
epilepsy and aged 20–40 years; use of phenytoin for at least 2 years
before enrollment, regular menstruation (for women), stable
weight (over the previous 6 months), stable dosage of phenytoin
(in the previous 6 months), no chronic medical illness other than
epilepsy, taking no medication except antiepileptic(s), with an
active daily life (able to perform activities of daily living without
assistance), no history of amenorrhoea, hysterectomy or oopho-
rectomy, and not consuming alcohol or smoking. Patients taking
other AEDs before inclusion, but who had stopped taking them at
least 2 years prior to the study period, were also included. The
exclusion criteria were: pregnancy; having signiﬁcant disability
such as mental retardation, ataxia, paresis, or other motor
disabilities, learning disability, language disorder, hearing or
visual disability; psychiatric disease; having a signiﬁcant medical
disorder other than epilepsy known to affect bone metabolism
such as hepatic, hematological, rheumatologic, renal or gastroin-
testinal disorder, hyperparathyroidism, hyperthyroidism, hypo-
gonadism, osteogenesis imperfecta, and fracture over the last year
prior to the study period; and taking medications known to affect
bone turnover, e.g., glucocorticoids, bisphosphonates, thiazides,
anticoagulants, GnRH analogs, vitamin D or A, calcium supple-
ment, hormonal replacement and steroids. Also, patients with a
family history of osteoporosis were excluded from the study.
The weight and height of the patients were measured and their
body mass index (BMI) was calculated [body weight (kg)/height
(m)2]. A body mass index in the range of 18.5–23.0 was considered
normal and one higher than 23.0 deemed as overweight, in
accordance with the World Health Organization (WHO) recom-
mendations.7 Blood samples were taken for albumin, calcium andphosphate level determination on a HITACHI 971 automatic
analyzer during the sample hospital visit. Additionally, the 25-
hydroxyvitamin D and parathyroid hormone levels were mea-
sured.
1.2. Serum 25-hydroxyvitamin D
The serum 25-hydroxyvitamin D level was measured in
duplicate via the HPLC method with UV detection (High Perfor-
mance Lipid Chromatography, HPLC; Agilent 1100, USA). The intra-
assay variability was less than 1.48% within a concentration range
of 64.74 ng/ml–68.70 ng/ml (normal range, 30 ng/ml–80 ng/ml).
Vitamin D deﬁciency was deﬁned as a 25-hydroxyvitamin D
level < 20 ng/ml and insufﬁciency as a level between 20 ng/ml and
29 ng/ml.10
1.3. Serum parathyroid hormone
The intact parathyroid hormone level was measured in
duplicate using electrochemiluminescence immunoassay (ECLIA;
Molecular Analytics E170, Germany). The detection limits were
1.20 pg/ml–5000 pg/ml. The intra-assay variability was less than
0.6% within a concentration range of 52.37 pg/ml–53.64 pg/ml
(normal range, 15 pg/ml–65 pg/ml).
1.4. Dual-energy absorptiometry
The bone mineral densities of the lumbar spine (L1–L4) and left
femur were measured by dual-energy X-ray absorptiometry (DXA)
(DXP MD Software version: 4.6, Lunar Corporation, USA) and
reported as a T-score (the difference in standard deviation units
between the measured bone density value and the peak bone
density in the normal reference population of Japanese population,
as supplied by the manufacturer, because no Thai reference was
available, and a Z-score [SD from age-sex-speciﬁc score in the
reference population]). The areas selected for the determination of
BMD were the neck of the left femur and the lumbar (L1–L4)
vertebrae. The WHO deﬁnes normal bone mineral density as a T-
score greater than -1.0, osteopenia as a T-score between > 2.5
and <1.0, and osteoporosis as a T-score <2.5. All of the patients
who had measurements taken at both sites were included in the
analysis.11
1.5. CYP2C9 genotyping
Genomic DNA was isolated from leukocyte nucleoids using a
QIAamp DNA Mini Kit (QIAGEN). Realtime HRM PCR (realtime
polymerase chain reaction high resolution melting) was performed
in a strip tube with a reaction volume of 20 ml, containing 2 ml of
SsoFast Evagreen Supermix ‘‘BioRad’’ (ready to use reactionmix),
0.15 mM of the forward and reverse primers for CYP2C9*2 and
CYP2C9*3, and 100 ng/ml of genomic DNA. The sequences of the
forward and reverse primers used were 50 TACAAATACAATGAAAA-
TATCATG 30 and 50CTAACAACCAGA CTCATAATG 30 for the
CYP2C9*2 (Arg144Cys) genotype, and the forward primer 50
AATAATAATATGCACGAGGTCCAGAGGTAC 30 and the reverse
primer 50 GATACTATGAATTTGGGACTT C 30 for the CYP2C9*3
(Ile359Leu) genotype (these primers were described by Ramasamy
et al.12 and synthesized by BioDesign Co., Ltd.).
Realtime PCR ampliﬁcation to detect CYP2C9*2 and/or CYP2C9*3
was performed using CFX 96 Connect Realtime-PCR (Bio-Rad
Laboratories, USA) with an initial denaturation at 95.0 8C for
3 min, followed by 40 cycles of denaturation at 95.0 8C for 10 s,
annealing at 59.0 8C for 15 s, and ﬁnal extension at 95.0 8C for 10 s. A
melt curve was plotted from 73.0 8C to 85.0 8C, with an increment
of 0.2 8C every10 s. The analysis of the melt curves used the
Table 1
Baseline demographics, bone mineral density, and blood chemistry of the study
population.
Variable CYP 2C9 genotype
Wild type
(76)
CYP 2C9
polymorphism (17)
Age
20–25 years 4 2
26–30 years 26 6
31–40 years 46 9
Sex (n)
Male 36 6
Female 40 11
Type of seizure
Simple with or without
generalization
35 9
Complex partial with or
without generalization
41 8
Serum PHT level mean (range) 16.6 (10–24) 18.9 (11–24)
10–20 mg/l 64 9
>20 mg/l 12 8
Seizure control
Seizure freea 54 12
Well-controlledb 22 5
Body mass index
<18.5 0 0
18.5–23.0 23 7
>23.0 53 10
Etiology (n)
Unknown 65 14
Head injury 5 1
CNS infection 6 2
Duration
<5 years 38 8
>5 years 38 9
Phosphate level
>4.5 mg/dl 1 1
2.5–4.5 mg/dl 73 16
<2.5 mg/dl 2 0
Calcium level
>10.2 mg/dl 0 0
9–10.2 mg/dl 53 11
<9 mg/dl 23 6
25-Hydroxyvitamin D level
<20 ng/ml 2 0
>20–29 ng/ml 12 1
>29 ng/ml 62 16
Parathyroid hormone level
<11 pg/ml 0 0
11–62 pg/ml 75 17
>62 pg/ml 1 0
Femoral neck T-score
<2.5 1 0
2.5 to 1 33 10
>1 42 7
Lumbar spine T-score
<2.5 3 0
2.5 to 1 32 4
>1 41 13
CYP, cytochrome P450; PHT, phenytoin.
a Deﬁned as seizure free for >24 months under AED therapy.
b Deﬁned as seizure free for 12 months under AED therapy.
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Analysis software version 1.1 (Bio-Rad Laboratories, USA). The
polymerase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) method used the same primer sets as the Realtime
PCR technique. PCR was performed at a reaction volume of 20 ml,
consisting of 2 ml of Top Taq Master Mix ready-to-use reaction mix
(QIAGEN), 0.2 mM each of the forward and reverse primers for
CYP2C9*2 and CYP2C9*3, and 100 ng/ml of genomic DNA. PCR was
performed in a S1000-PCR thermal cycler (Bio-Rad Laboratories,
USA) with an initial denaturation at 94.0 8C for 4 min, followed by 40
cycles of denaturation at 95.0 8C for 30 s, annealing at 56.0 8C for
30 s, extension at 72.0 8C for 45 s and ﬁnal extension at 72.0 8C for
10 min. Eight microliters of alliquot from each PCR product were
digested with 5 U of restriction enzymes AvaII (Promega) and 5 U of
Kpn I (Takara) for CYP2C9*2 and CYP2C9*3, respectively. Incubation
was done at 37.0 8C overnight. The detection of the digested product
was performed with 12% polyacrylamide gel electrophoresis, using
120 V for 2.5 h. The PCR-RFLP results were randomly selected to be
conﬁrmed by direct nucleotide sequencing on an ABI 3130 Genetic
Analyzer and 3130 Collection Software.
We classiﬁed the patients into two groups: (1) the CYP2C9
polymorphism gene group, which included patients who were
homozygous or heterozygous CYP2C9*3 and (2) the wild-type gene
of 2C9*1.
The Ethics Review Committee of the Faculty of Medicine, Prince
of Songkla University, approved the study and informed consent
was sought and obtained from all of the patients.
1.6. Statistical analysis
The characteristics of the study patients were described in
terms of mean and standard deviation for continuous variables,
and number and percentage for categorical variables. Comparisons
of continuous variables between two subgroups of subjects were
performed using a two-tailed t-test or Mann–Whitney test if
Shapiro–Wilks test revealed evidence of non-normality within
either group. Correlations between serum phenytoin, serum PTH,
serum 25-hydroxyvitamin D and BMD parameters in the group
with CYP2C9 polymorphism were explored using the Pearson
product movement correlation coefﬁcient. The independent effect
of CYP2C9 polymorphism on BMD was explored by multivariate
linear regression modeling in which sex, age, BMI, and serum levels
of phenytoin, 25-hydroxyvitamin D level and parathyroid hor-
mone were included as covariates. p-Values of <0.05 were
considered to be statistically signiﬁcant. All statistical analyses
were performed using Stata version 7.0 (Stata Statistical Software:
version 7.0, College Station, TX, USA).
2. Results
All of the 93 young adult epilepsy patients who were invited to
participate in the study agreed to participate. All of the participants
had focal epilepsy with or without generalized tonic clonic
epilepsy and were taking phenytoin as monotherapy. The basic
demographic and clinical characteristics of the patients are shown
in Table 1. The mean  SD age was 31.93  4.60 years (range: 20–40
years), 45.2% were male and 54.8% female. The mean duration of
treatment  SD with antiepileptic drugs for the overall group at the
time of the study was 5.4  1.7 years (range: 2.5–9 years). Concerning
the frequency of each genotype of CYP P450 2C9, about 14% (13 out of
93) of epilepsy patients were found to be CYP2C9*3 heterozygous
carriers (wt/mt) and 4.3% (4 out of 93) were CYP2C9*3 homozygous
(mt/mt), which is characterized by the phenotype with poor
phenytoin metabolism. No homozygous or heterozygous CYP2C9*2
carriers were found.In the epilepsy patients with CYP 2C9 polymorphism, of the
total 17 subjects, 6 were male and 11 female, having a mean  SD
age of 31.7  5.2 years (range 20–39). Shapiro–Wilks test revealed no
evidence of non-normality of any variables within either group and 2-
tailed t-test was therefore used for all comparisons. There was no
signiﬁcant difference between the patients with wild type and the
Table 2
Clinical characteristics, mean levels of biochemical parameters, parathyroid hormone and 25-hydroxyvitamin D levels, and BMD according to the genotype of the vitamin D
receptor.
Variable CYP 2C9 genotype p-value
Wild type (76) CYP 2C9 polymorphism (17)
Mean  SD 95% CI Mean  SD 95% CI
Age (years) 32.0  4.5 30.9–33.0 31.7  5.2 29.0–34.4 0.83
Sex (male:female) (n) 36:40 6:11 0.43
Duration of phenytoin (years) 5.4  1.7 5.0–5.8 5.5  1.7 4.6–6.4 0.73
25-Hydroxyvitamin D level (ng/ml) 38.3  10.6 35.9–40.8 44.8  13.5 37.9–51.7 0.03
Serum PHT level (mg/l; mean  SD) 16.6  3.3 15.9–17.4 18.9  4.0 16.9–21 0.01
Parathyroid hormone level (pg/ml) 49.0  13.4 45.9–52.1 42.2  9.6 37.2–47.1 0.05
Phosphate level (mg/dl) 3.34  0.53 3.22–3.46 3.24  0.54 2.97–3.52 0.47
Calcium level (mg/dl) 9.11  0.37 9.02–9.19 9.11  0.35 8.94–9.30 0.91
BMI 24.2  2.2 23.7–24.8 23.8  2.4 22.6–25.1 0.49
Femoral neck Z-score 0.77  0.76 0.94 to (0.59) 0.36  0.6 0.67 to (0.05) 0.04
Lumbar spine Z-score 0.03  1.07 0.22 to 0.27 0.60  1.47 0.15 to 1.350 0.06
Femoral neck T-score 0.86  0.78 1.04 to (0.68) 0.30  1.14 0.89 to 0.29 0.02
Lumbar spine T-score 0.02  1.09 0.23 to 0.27 0.38  1.52 0.40 to 0.16 0.27
CYP, cytochrome P450; PHT, phenytoin; BMI, body mass index.
K. Phabphal et al. / Seizure 22 (2013) 766–771 769patients with CYP 2C9 polymorphism in terms of sex and age (p = 0.43
and p = 0.83, respectively). Likewise, the duration of treatment  SD
did not differ signiﬁcantly between the groups; the patients with CYP
2C9 polymorphism and the patients with the wild type had means
durations treatment of 5.5  1.7 years (range: 3–8 years) and
5.4  1.7 years (range: 2.5–9 years), respectively (p = 0.73). The
mean  SD BMI in the patients with CYP 2C9 polymorphism was
23.8  2.4; 7 had a normal value for BMI, no patient had a low BMI
and 10 were overweight. The mean  SD BMI of patients with wild
type was 24.2  2.2; 23 had a normal value for BMI, no patient had a
low BMI and 53 were overweight. Overall, there was no signiﬁcant
difference between the two groups in BMI (p = 0.49). The means  SD
of phosphate and calcium levels were 3.24  0.54 vs. 3.34  0.53 and
9.11  0.35 vs. 9.11  0.37 in the patients with CYP 2C9 polymor-
phism and the patients with wild type, respectively. The other basic
demography characteristics are shown in Tables 1 and 2. None of the
demographic variables showed any signiﬁcant difference between
the two groups. The patients with CYP 2C9 polymorphism had higher
plasma levels of phenytoin when compared with the patients with
wild type (p = 0.01).
2.1. Blood chemistry and bone mineral density
The mean  SD serum 25-hydroxyvitamin D levels in the patients
with CYP 2C9 polymorphism was 44.8  13.5 ng/ml. No patient had a
level of <20 ng/ml, which would have indicated 25-hydroxyvitamin
D deﬁciency. One patient (5.9%) had a level between >20 ng/ml and
29 ng/ml, suggesting 25-hydroxyvitamin D insufﬁciency. Overall, we
found an association between low 25-hydroxyvitamin D and low
BMD at the femoral neck. Moreover, the mean  SD of serum 25-
hydroxyvitamin D levels in the wild-type patients was
38.3  10.6 ng/ml. Two patients (2.6%) had levels of <20 ng/ml,
which indicated 25-hydroxyvitamin D deﬁciency and 12 others
(15.8%) had levels between >20 ng/ml and 29 ng/ml, suggesting 25-
hydroxyvitamin D insufﬁciency. There was a statistically signiﬁcant
(p = 0.03) lower mean serum 25-hydroxyvitamin D levels among
patients with wild type when compared with their counterparts with
CYP 2C9 polymorphism (Table 2). Furthermore, there was marginal
evidence of higher serum PTH levels in patients with wild type
compared patients with CYP 2C9 polymorphism (p = 0.05). Serum
calcium concentrations and serum phosphate levels were not
signiﬁcantly different between the two groups (p = 0.91 and
p = 0.47, respectively).
The bone mineral density results are shown in Table 2. BMD was
associated with CYP 2C9 polymorphism in the epilepsy patients.Speciﬁcally, patients with CYP 450 2C9*3 (homozygotes and
heterozygotes) had higher T-scores  SD and Z-scores  SD of the
femoral neck than those with wild type (p = 0.02 and 0.04,
respectively). However, this was not the case with T-scores  SD
and Z-scores  SD of the lumbar spine (p = 0.27 and 0.06, respective-
ly). The wild-type patients’ mean T-scores  SD and Z-scores  SD of
the femoral neck were -0.86  0.78 and -0.77  0.76, respectively.
Osteopenia at the femoral neck was detected in 58.8% of patients with
CYP 2C9 polymorphism and 43.4% of patients with wild type.
Additionally, we found osteoporosis in the wild-type patients at the
rate of 1.3% (1 of 76 patients). CYP2C9 polymorphism remained the
only variable signiﬁcantly related to femoral neck T- and Z-scores in
multivariate modeling after adjusting for duration of therapy, sex,
age, BMI, and serum levels of phenytoin, 25-hydroxyvitamin D, and
parathyroid hormone. Surprisingly, no correlation between serum
phenytoin levels and BMD at the femoral neck or at the lumbar spine
was detected.
3. Discussion
Epilepsy patients receiving the CYP P450 enzyme-inducing
AED, phenytoin, and who had the CYP 2C9 polymorphism had
higher T-scores and Z-scores of the femoral neck (p = 0.02 and 0.04,
respectively), but not of the lumbar spine (p = 0.27 and 0.06,
respectively) than the wild-type patients. However, we did not
detect any correlation between serum phenytoin level and BMD.
Nevertheless, the mean serum PTH level tended to be lower
among patients with CYP 2C9 polymorphism when compared with
the patients with wild type (p = 0.05). Interestingly, the mean
serum 25-hydroxyvitamin D levels was statistically signiﬁcantly
lower in wild-type patients than in those with 2C9 polymorphism
(p = 0.03).
The CYP P450 super family represents one group of important
Phase-I drug-metabolizing enzymes that oxidize a number of
endogenous compounds and xenobiotics, including more than 90%
of the current therapeutic drugs.13 Approximately 40% of the white
and 5% of the Asian or black populations are heterozygous for
either CYP2C9*2 or CYP2C9*3.9 In Thailand, Kuanprasert et al.
conducted a study on valvular heart disease in Northern Thailand
and found that 95% of the 242 patients under investigation had
CYP2C9*1/*1; CYP2C9*1/*3 was found in the remaining 5%. Neither
the mutant CYP2C9*2 allele nor the individual homozygote for
CYP2C9*3 was found.14 However, our study found that the CYP 2C9
mutation had a prevalence of 18.3%. About 14% (13 out of 93) of our
epilepsy patients were found to be CYP2C9*3 heterozygous carriers
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mt). No homozygous or heterozygous CYP2C9*2 carriers were
found. Our study was conducted in a location in Southern Thailand
near the Malaysian border. The Gan et al. study in patients who live
in Malaysia (91 Malays, 96 Chinese, and 46 Indian patients) found
that the prevalence of CYP2C9 polymorphism in that population
ranged from 8% to 15%.15 The higher prevalence of CYP2C9
polymorphism in our study compared with that from Northern
Thailand; may be explained by the history of ethnic mixing
between the Thais and Malaysian in the southern region. There has
been no study of the prevalence of CYP 2C9 polymorphism in the
healthy general population in Thailand.
Our study found that epilepsy patients who had heterozy-
gous or homozygous CYP2C9*3 had higher serum phenytoin
levels than those who had the wild type. A few investigators
have reported an association between serum antiepileptic drug
level and BMD or blood bone biomarkers. The dose of phenytoin
related to effects on bone health has been identiﬁed by Nakade
et al.8 They conducted a study on the effects of phenytoin on
human-mandible-derived bone cells and noted that the osteo-
genic effects of phenytoin on human-mandible-derived bone
cells were biphasic. However, the possibility that the dose-
dependent situation in vivo could be different from the in vitro
one is real. Lau et al., who conducted a study in male epilepsy
patients taking phenytoin, also found that the serum levels of
osteocalcin, skeletal alkaline phosphatase, and procollagen
peptides were signiﬁcantly correlated with the serum phenytoin
level, but not with the dose or duration of phenytoin treatment.7
Moreover, we found a higher BMD at the femoral neck in
epilepsy patients who had CYP2C9*3 (heterozygous or homozy-
gous) than those carrying the wild type allele. In this study, we
did not detect a correlation between serum phenytoin and BMD
at the femoral neck in CYP 2C9*3 polymorphism (homozygous
or heterozygous) as well as wild type after adjusting for
potentially confounding factors such as age, sex, duration of
treatment with phenytoin, 25-hydroxyvitamin D, and parathy-
roid hormone.
Previous studies have reported that epilepsy patients taking
antiepileptic drugs had low 25-hydroxyvitamin D levels, ranging
from 11% to 77%.16,17 An earlier study has suggested that phenytoin
induces bone loss via the CYP P450 enzyme-inducing antiepileptic
drugs, which leads to an increased metabolism of 25-hydro-
xyvitamin D.18 This mechanism is supported by our ﬁndings
because they indicate that low serum 25-hydroxyvitamin D levels
were associated with low BMD in epilepsy patients taking
phenytoin. In our study, we found that epilepsy patients with
wild-type CYP 2C9 had lower 25-hydroxyvitamin D levels than
epilepsy patients with CYP 2C9 polymorphism (p = 0.03). Reduc-
tions in 25-hydroxyvitamin D can result in malabsorption of
calcium and secondary hyperparathyroidism. According to previ-
ous clinical studies, the incidence of hypocalcemia in patients
being treated with anticonvulsants is 4–30%.19,20 Nevertheless, in
previous experimental studies, the cause of hypocalcemia in rats
treated with various doses of phenytoin (1–150 mg/kg/day) was
not determinable.21 Our study found low 25-vitamin D levels and
hypocalcemia at the rates of 18.4% and 30.3% in the wild-type
individuals and 5.9% and 35.3% in those with CYP 2C9 polymor-
phism. Furthermore, we did not ﬁnd a signiﬁcant serum calcium
level difference between the two groups (p = 0.91). Likewise, we
did not observe any association between serum calcium or 25-
hydroxyvitamin D levels and serum phenytoin level. Typically,
hyperparathyroid conditions are characterized by a depletion of
the cortical bone and conservation of the trabecular bone.22 That
study resulted in reduced BMD level, which, in respect of patients
with wild-type CYP 2C9, primarily affects the femoral neck that is
fundamentally composed of cortical bone. Yet, we found nosigniﬁcant alteration of BMD in the lumbar spine where the
composition is mostly trabecular bone. Moreover, the present
study conﬁrmed that parathyroid hormone levels in epilepsy
patients taking phenytoin are not associated with low BMD at
either site. Again, we did not detect any correlation between
serum phenytoin and BMD at either site. Overall, the serum
parathyroid hormone level was not signiﬁcantly different
between epilepsy patients with wild type and CYP 2C9
polymorphism. Hence, the possible mechanism at hand
is something other than a hyperparathyroid state. This ﬁnding
is supported by those of a previous study that was also
conducted in a tropical Asian country on both CYP P450-inducer
and non-inducer AEDs among young adult epilepsy patients,
which reported that the parathyroid hormone level was not
associated with low BMD.4 This result contrasts with those from
studies conducted in Western countries. This is probably
explained by the fact that our patients were on an ambulatory
regimen and not institutionalized as they would have been in
the past. Another important factor is the differences in the diet
between the study populations. The nutritional contribution
together with other sources of vitamin D, like exposure to the
sun, may contribute to the maintenance of some normal
deposits of this vitamin despite the possible negative metabolic
effect of hepatic degradation of vitamin D produced by
phenytoin.17 Another suggested possible mechanism for low
BMD is the direct action of phenytoin on bone resorption and
bone formation.7
This investigation has a number of important limitations due to
a lack of data on calcium intake; dietary intake estimated using the
recall technique over a short period of time may not be a good
representation of usual or long-term calcium intake. Reports of
previous studies, however, have failed to demonstrate a statisti-
cally signiﬁcant effect of dietary calcium on parameters of bone
health.23 Another limitation is our failure to provide bone
remodeling markers in this study; however, we believe the results
are of interest and contribute to the body of knowledge on the
effects of AEDs on the skeleton in the setting of CYP 2C9
polymorphism.
The following strengths of this study are that; ﬁrstly, it is the
ﬁrst study to explore the relationship between CYP 2C9 polymor-
phism, serum phenytoin concentration and BMD in young adult
epilepsy patients taking phenytoin as monotherapy, allowing on
investigation of the association between CYP 2C9 gene polymor-
phism and BMD, 25-hydroxyvitamin D or parathyroid hormone
levels. We also included a homogenous sample population.
Secondly, the measurement of 25-hydroxyvitamin D and parathy-
roid hormone levels as well as those of CYP 2C9 gene polymor-
phism and BMD used modern techniques and appropriate sites
(femur neck and lumbar spine). We excluded patients with
potential confounding factors that are known to affect BMD,
especially fracture within 1 year before inclusion, smoking, alcohol
consumption, abnormal menstruation, use of hormonal drugs, and
recent weight change. Thus, our study should be able to evaluate a
true association between CYP 2C9 gene polymorphism and BMD,
25-hydroxyvitamin D or parathyroid hormone levels in young
adult epilepsy patients.
In conclusion, this is the ﬁrst time that the association between
young epilepsy patients taking phenytoin and CYP 2C9 gene
polymorphism or parathyroid hormone or 25-hydroxyvitamin D
levels has been investigated. Our study conﬁrms that epilepsy
patients carrying the CYP2C9*3 polymorphism (heterozygous or
homozygous) had higher serum phenytoin levels than those with
the wild-type allele (CYP2C9*1). Moreover, we found a higher BMD
in epilepsy patients with CYP2C9*3 (heterozygous or homozygous)
than wild-type ones. However, we did not detect a correlation
between serum phenytoin levels and BMD at the femoral neck or
K. Phabphal et al. / Seizure 22 (2013) 766–771 771lumbar spine. In a future study, we will evaluate the best choice
AED for long term treatment of epilepsy patients with CYP2C9*3.
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